human ace2 tmprss2 expressing a549 cells  (InvivoGen)

Journal: Vaccines

Article Title: Expression of SARS-CoV-2 Spike Protein Receptor Binding Domain on Recombinant B. subtilis on Spore Surface: A Potential COVID-19 Oral Vaccine Candidate

doi: 10.3390/vaccines10010002

Figure Lengend Snippet: ( A ) Schematic presentation of the immunization schedule in humans. Healthy volunteers were orally administered with 5 × 10 7 spores/kg person of B. subtilis spores for three courses. ( B ) The antibody titers targeting the RBD of SARS-CoV-2 were measured with a CLIA-based assay. Each connected dot represents one individual. ( C , D ) Representative plot of pseudovirus neutralizing assay. Serum samples from immunized volunteers were pre-incubated with wild type ( C ) or D614G (D) SARS-CoV-2 pseudoviruses carrying a GFP reporter gene and added to human lung carcinoma cell A549 expressing human ACE2 and TMPRSS2. The percentages of infected cells over serum dilution were fitted with non-linear regression. ( E , F ) The serum dilution resulting in a 50% reduction in infection was designated as EC 50 . Each connected dot represents one individual. ** p < 0.01, *** p < 0.001, two-way ANOVA; number of volunteers = 6.

Article Snippet: Human lung carcinoma cell line A549 expressing ACE2 and TMPRSS2 (InvivoGen, cat. no. A549-HACE2TPSA) was plated in a 96-well plate at a density of 1 × 10 5 /well and incubated with pre-incubated pseudoviruses.

Techniques: Neutralizing Assay, Incubation, Expressing, Infection